In the course of developing our phenotype, we noted a high degree of overlap between the ALT-based NAFLD phenotype (ALT-threshold) and one that required a concomitant metabolic risk factor (ALT-metabolic). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.